Immunogenicity and Tolerance of Two Strategies of Anti-HAV Vaccination in HIV-infected Patients
Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
Immunogenicity is reduced in immunocompromised patients. The aim of this prospective
randomized study is to evaluate tolerance and immunogenicity of 2 doses versus 3 doses of
anti-HAV vaccine in HIV-1 infected patients with CD4 count between 200 and 500 per mm3,
co-infected or not with HBV and/or HCV. The factors influencing vaccine immunogenicity will
be evaluate.